Tirzepatide is an innovative dual GIP and GLP-1 receptor agonist, representing a significant advancement in the management of type 2 diabetes and chronic weight management. Developed with precision, it offers a comprehensive approach to metabolic health.
Dual Receptor Agonism
- Targets both GIP and GLP-1 receptors for enhanced glucose control.
- Promotes insulin secretion in a glucose-dependent manner.
- Suppresses glucagon secretion, reducing hepatic glucose production.
Comprehensive Metabolic Impact
- Significant HbA1c reduction in clinical trials.
- Supports substantial weight loss in patients with obesity.
- May improve cardiovascular risk factors.
| Parameter | Detail |
|---|---|
| Active Ingredient | Tirzepatide |
| Drug Class | Dual GIP and GLP-1 Receptor Agonist |
| Formulation | Solution for Injection |
| Available Strengths | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Administration Route | Subcutaneous |
| Storage Conditions | Refrigerate (2°C to 8°C), do not freeze |
For optimal results, follow these general guidelines. Always consult the full prescribing information for detailed instructions.
- Initiate treatment with the lowest recommended dose (e.g., 2.5 mg once weekly).
- Gradually titrate the dose upwards based on patient response and tolerability.
- Administer once weekly at any time of day, with or without meals.
- Inject subcutaneously into the abdomen, thigh, or upper arm.
- Rotate injection sites with each dose.
Tirzepatide may cause side effects. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain. Serious side effects may include pancreatitis, gallbladder problems, kidney problems, severe stomach problems, and allergic reactions. Do not use if you or your family have a history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
For healthcare professionals, detailed clinical trial data and prescribing information are available upon request. Patients should discuss any questions or concerns with their healthcare provider.
Contact us for more information or to request a product brochure.
